Patents Assigned to PELICAN THERAPEUTICS, INC.
  • Anti-TNFRSF25 antibodies
    Patent number: 10683359
    Abstract: Anti-TNFRSF25 antibodies and variants thereof, including those that bind to an epitope in the region of amino acids 48-71, are disclosed. Also contemplated are uses of the antibodies in research, diagnostic, and therapeutic applications.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: June 16, 2020
    Assignee: Pelican Therapeutics, Inc.
    Inventors: Taylor H. Schreiber, Jeff T. Hutchins
  • Human TNFRSF25 antibody
    Patent number: 10683358
    Abstract: Antibodies and antigen binding fragments that bind specifically to TNFRSF25 are provided herein. Methods for using the antibodies and antigen binding fragments to, for example, stimulate proliferation of human T cells (e.g., CD8+ T cells) and to treat cancer patients also are provided.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: June 16, 2020
    Assignee: Pelican Therapeutics, Inc.
    Inventor: Taylor H. Schreiber
  • Anti-TNFRSF25 antibodies
    Patent number: 10005843
    Abstract: Anti-TNFRSF25 antibodies and variants thereof, including those that bind to an epitope in the region of amino acids 48-71, are disclosed. Also contemplated are uses of the antibodies in research, diagnostic, and therapeutic applications.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 26, 2018
    Assignee: PELICAN THERAPEUTICS, INC.
    Inventors: Taylor H. Schreiber, Jeff T. Hutchins
  • Human TNFRSF25 antibody
    Patent number: 9982057
    Abstract: Antibodies and antigen binding fragments that bind specifically to TNFRSF25 are provided herein. Methods for using the antibodies and antigen binding fragments to, for example, stimulate proliferation of human T cells (e.g., CD8+ T cells) and to treat cancer patients also are provided.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: May 29, 2018
    Assignee: PELICAN THERAPEUTICS, INC.
    Inventor: Taylor H. Schreiber